Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Unlike other malignancies, the death rate of bladder cancer has not declined in several decades, highlighting the need for new treatment options. In the emerging era of immunotherapy, therapeutic cancer vaccines are an attractive option to cure, control and prevent cancer. Despite this, finding a feasible and efficacious vaccine platform has proven elusive across all malignancies. Vesigenurtacel-L is the first whole cell, allogeneic vaccine intended to treat high-grade, nonmuscle invasive bladder cancer. This type of vaccine technology for bladder cancer is novel, and has the potential to be both economically and logistically feasible.

Original languageEnglish (US)
Pages (from-to)2673-2682
Number of pages10
JournalFuture Oncology
Volume12
Issue number23
DOIs
StatePublished - Dec 1 2016

Fingerprint

Urinary Bladder Neoplasms
Vaccines
Neoplasms
Cancer Vaccines
Immunotherapy
Technology
Mortality
Therapeutics

Keywords

  • allogeneic
  • bladder cancer
  • immunotherapy
  • nonmuscle invasive
  • therapeutic vaccine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer. / Keehn, Aryeh; Gartrell, Benjamin A.; Schoenberg, Mark P.

In: Future Oncology, Vol. 12, No. 23, 01.12.2016, p. 2673-2682.

Research output: Contribution to journalArticle

@article{d16488e9e97548cc9d1f83dce0b54af9,
title = "Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer",
abstract = "Unlike other malignancies, the death rate of bladder cancer has not declined in several decades, highlighting the need for new treatment options. In the emerging era of immunotherapy, therapeutic cancer vaccines are an attractive option to cure, control and prevent cancer. Despite this, finding a feasible and efficacious vaccine platform has proven elusive across all malignancies. Vesigenurtacel-L is the first whole cell, allogeneic vaccine intended to treat high-grade, nonmuscle invasive bladder cancer. This type of vaccine technology for bladder cancer is novel, and has the potential to be both economically and logistically feasible.",
keywords = "allogeneic, bladder cancer, immunotherapy, nonmuscle invasive, therapeutic vaccine",
author = "Aryeh Keehn and Gartrell, {Benjamin A.} and Schoenberg, {Mark P.}",
year = "2016",
month = "12",
day = "1",
doi = "10.2217/fon-2016-0284",
language = "English (US)",
volume = "12",
pages = "2673--2682",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "23",

}

TY - JOUR

T1 - Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer

AU - Keehn, Aryeh

AU - Gartrell, Benjamin A.

AU - Schoenberg, Mark P.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Unlike other malignancies, the death rate of bladder cancer has not declined in several decades, highlighting the need for new treatment options. In the emerging era of immunotherapy, therapeutic cancer vaccines are an attractive option to cure, control and prevent cancer. Despite this, finding a feasible and efficacious vaccine platform has proven elusive across all malignancies. Vesigenurtacel-L is the first whole cell, allogeneic vaccine intended to treat high-grade, nonmuscle invasive bladder cancer. This type of vaccine technology for bladder cancer is novel, and has the potential to be both economically and logistically feasible.

AB - Unlike other malignancies, the death rate of bladder cancer has not declined in several decades, highlighting the need for new treatment options. In the emerging era of immunotherapy, therapeutic cancer vaccines are an attractive option to cure, control and prevent cancer. Despite this, finding a feasible and efficacious vaccine platform has proven elusive across all malignancies. Vesigenurtacel-L is the first whole cell, allogeneic vaccine intended to treat high-grade, nonmuscle invasive bladder cancer. This type of vaccine technology for bladder cancer is novel, and has the potential to be both economically and logistically feasible.

KW - allogeneic

KW - bladder cancer

KW - immunotherapy

KW - nonmuscle invasive

KW - therapeutic vaccine

UR - http://www.scopus.com/inward/record.url?scp=84995505530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995505530&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0284

DO - 10.2217/fon-2016-0284

M3 - Article

C2 - 27609194

AN - SCOPUS:84995505530

VL - 12

SP - 2673

EP - 2682

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 23

ER -